4/12
08:00 am
arvn
Arvinas, Inc. (NASDAQ: ARVN) had its price target lowered by analysts at HC Wainwright from $90.00 to $87.00. They now have a "buy" rating on the stock.
Medium
Report
Arvinas, Inc. (NASDAQ: ARVN) had its price target lowered by analysts at HC Wainwright from $90.00 to $87.00. They now have a "buy" rating on the stock.
4/11
04:08 pm
arvn
Arvinas And Novartis Partnering On Prostate Cancer Protein Degrader Is A Win-Win Situation [Seeking Alpha]
Low
Report
Arvinas And Novartis Partnering On Prostate Cancer Protein Degrader Is A Win-Win Situation [Seeking Alpha]
4/11
10:28 am
arvn
Dow Jones Lower Despite PPI Inflation Relief; Nvidia, Microsoft Price Targets Raised [Yahoo! Finance]
Low
Report
Dow Jones Lower Despite PPI Inflation Relief; Nvidia, Microsoft Price Targets Raised [Yahoo! Finance]
4/11
07:51 am
arvn
UPDATE 1-Novartis licenses Arvinas' cancer drug for up to $1 billion [Yahoo! Finance]
Medium
Report
UPDATE 1-Novartis licenses Arvinas' cancer drug for up to $1 billion [Yahoo! Finance]
4/11
07:25 am
arvn
Novartis licenses Arvinas' cancer drug for up to $1 billion [Yahoo! Finance]
Medium
Report
Novartis licenses Arvinas' cancer drug for up to $1 billion [Yahoo! Finance]
4/11
07:22 am
arvn
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer [Yahoo! Finance]
Medium
Report
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer [Yahoo! Finance]
4/11
07:00 am
arvn
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
Low
Report
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
4/4
09:01 am
arvn
An Ingenious Technology Could Change Both Medicine And Agriculture [Forbes]
Low
Report
An Ingenious Technology Could Change Both Medicine And Agriculture [Forbes]
3/25
01:01 pm
arvn
Arvinas, Inc. (NASDAQ: ARVN) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $65.00 price target on the stock.
Low
Report
Arvinas, Inc. (NASDAQ: ARVN) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $65.00 price target on the stock.
3/19
02:33 am
arvn
Arvinas gets new chief medical head [Seeking Alpha]
Low
Report
Arvinas gets new chief medical head [Seeking Alpha]
3/18
04:46 pm
arvn
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer [Yahoo! Finance]
Low
Report
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer [Yahoo! Finance]
3/18
04:40 pm
arvn
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
Low
Report
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
3/4
07:17 am
arvn
Arvinas to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Arvinas to Participate in Upcoming Investor Conferences [Yahoo! Finance]
3/4
07:00 am
arvn
Arvinas to Participate in Upcoming Investor Conferences
Low
Report
Arvinas to Participate in Upcoming Investor Conferences
3/3
07:00 am
arvn
Arvinas: Behind The Huge Rally [Seeking Alpha]
Low
Report
Arvinas: Behind The Huge Rally [Seeking Alpha]
3/1
05:49 am
arvn
Arvinas, Inc. (NASDAQ:ARVN) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock? [Yahoo! Finance]
Low
Report
Arvinas, Inc. (NASDAQ:ARVN) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock? [Yahoo! Finance]
2/29
09:10 am
arvn
Arvinas, Inc. (NASDAQ: ARVN) had its price target raised by analysts at Barclays PLC from $26.00 to $60.00. They now have an "overweight" rating on the stock.
Low
Report
Arvinas, Inc. (NASDAQ: ARVN) had its price target raised by analysts at Barclays PLC from $26.00 to $60.00. They now have an "overweight" rating on the stock.
2/28
01:10 pm
arvn
Arvinas, Inc. (NASDAQ: ARVN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Low
Report
Arvinas, Inc. (NASDAQ: ARVN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
2/28
10:26 am
arvn
Is a Surprise Coming for Arvinas (ARVN) This Earnings Season? [Yahoo! Finance]
Neutral
Report
Is a Surprise Coming for Arvinas (ARVN) This Earnings Season? [Yahoo! Finance]
2/28
09:13 am
arvn
Arvinas, Inc. (NASDAQ: ARVN) had its price target raised by analysts at BMO Capital Markets from $89.00 to $90.00. They now have an "outperform" rating on the stock.
Medium
Report
Arvinas, Inc. (NASDAQ: ARVN) had its price target raised by analysts at BMO Capital Markets from $89.00 to $90.00. They now have an "outperform" rating on the stock.
2/28
08:17 am
arvn
Arvinas, Inc. (NASDAQ: ARVN) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $80.00 price target on the stock, down previously from $95.00.
Medium
Report
Arvinas, Inc. (NASDAQ: ARVN) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $80.00 price target on the stock, down previously from $95.00.
2/28
08:17 am
arvn
Arvinas, Inc. (NASDAQ: ARVN) had its price target raised by analysts at Wedbush from $33.00 to $59.00. They now have an "outperform" rating on the stock.
Medium
Report
Arvinas, Inc. (NASDAQ: ARVN) had its price target raised by analysts at Wedbush from $33.00 to $59.00. They now have an "outperform" rating on the stock.
2/28
05:30 am
arvn
Arvinas, Inc. (NASDAQ: ARVN) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.
Low
Report
Arvinas, Inc. (NASDAQ: ARVN) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.
2/27
07:38 am
arvn
Arvinas GAAP EPS of -$2.53 misses by $1.38, revenue of $43.1M misses by $92.4M [Seeking Alpha]
Low
Report
Arvinas GAAP EPS of -$2.53 misses by $1.38, revenue of $43.1M misses by $92.4M [Seeking Alpha]
2/27
07:12 am
arvn
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
Low
Report
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]